We have established a new chemiluminescent enzyme immunoassay for Carcinoembryonic antigen (CEA), designated ACCESS CEA, which is adapted to the fully automated ACCESS® immunoassay analyzer. The assay is based on a one step sandwich-type method using two monoclonal antibodies, one of which is immobilized on micrometer-size paramagnetic particles and the other is conjugated to alkaline phosphatase. Ten microliters of calibrators or sera are incubated for 5 minutes at 37 °C with the particles and with the alkaline phosphatase conjugate. The particles are then magnetically separated and washed to remove unbound components. Time needed to obtain the first result is less than 15 minutes.
Introduction
20 CEA-related antigens, such as non-specific cross-re-_ .
. their reactivities with CEA and main CEA-related antiAlthough various immunoassay systems for CEA are gens (9, 10) . Furthermore, these monoclonal antibodies currently available, the CEA values obtained are highly have been classified into 7 groups (groups A-G) in variable depending on the assay kit used (3) (4) (5) . This is light of the domain structure of the CEA molecule thought to be due to the diverse structures of the carbo- (11, 12) . Among them, group F monoclonal antibodies hydrate chains of the CEA molecule (6, 7), which lead have been found to discriminate CEA in tumour tisto variation in specificity of anti-CEA antibody prepara-sues from die CEA-related antigens (13) . The tions used in the assay kits (8) . On the other hand, about immunoassay systems for CEA utilizing at least one group F monoclonal antibody have shown improved cancer diagnosis (14, 15) .
Recent attempts, however, have concentrated on the development of automated immunoassay analyzers with sensitive and precise assay reagents, which also reduce turn-around time, stuff usage and volume of disposables and assay costs, and several automated non-isotopic immunoassay systems have been introduced for estimation of various analytes including CEA (16) . Of these, the ACCESS® immunoassay analyzer (Sanofi Diagnostics Pasteur, Inc., Chaska, MN, USA) is a fully automated laboratory assay system for enzyme immuneassays (ElAs) with the term random access relating to the concept of flexible assay processing and with continuous access i. e., the ability to interrupt an analyzer run, add stat or additional routine specimens, and continue the run with no loss of results (16, 17) .
In the present study, by using two defined monoclonal antibodies, including a .Group F monoclonal antibody, we tried to establish a new immunoassay for CEA, designated ACCESS CEA, which is adapted to the fully automated ACCESS® immunoassay analyzer. We further evaluated the ACCESS CEA assay in the CEA determinations of patients' serum samples, and compared it with the established IMx CEA assay.
Materials and Methods

Carcinoembryonic antigen and related normal antigens
Four different CEA preparations, designated CEA-DB, CEA-MY, CEA-TT, and CEA-TY, were purified from liver metastases from colorectal carcinomas by treatment with phosphatidylinositol-specific phospholipase C followed by perchloric acid extraction and gel filtration as previously described (18) . Non-specific cross-reacting antigen and non-specific cross-reacting antigen-2 were purified from pooled normal human lung (19) and meconium (20) , respectively. Normal faecal antigen-1 and normal faecal antigen-2 were obtained from normal adult faeces (21) . The non-specific crossreacting antigen and normal faecal antigen-1 are partially crossreactive with CEA but antigenically unrelated to each other (22) . The purity of each antigen preparation was ensured by the demonstration of a single component on immunoelectrophoresis and by sodium dodecyl sulphate polyacrylamide gel electrophoresis (20, 21) , and was also defined by a single NH 2 -terminal amino acid (22, 23) . The concentrations in weight of all antigens were estimated from the absorption coefficient of each antigen (5).
Monoclonal antibodies
Two mouse anti-CEA monoclonal antibodies (F82-61 and Fll-39) were prepared as described by Kuroki et al. (10, 12) . Both monoclonal antibodies were of IgGl (12) . The monoclonal antibodies were purified from ascitic fluids by ammonium sulphate precipitation and protein A chromatography. Purified monoclonal antibody F82-61 was immobilized on micrometre-size paramagnetic particles (Rhone-Poulenc Chimie, Lyon Cedex, France) as capture antibody as described previously (24) . The antibody fragment Fab' of monoclonal antibody Fl 1-39 was prepared with pepsin digestion followed by gel filtration on a TSK G3000SW column and reduction with 2-mercaptoethylamine HC1 as described by Hashida et al. with slight modifications (25) , and conjugated to alkaline phosphatase (Boehringer Mannheim GmbH, Mannheim, Germany) as tracer antibody.
Instruments
The ACCESS® immunoassay analyzer has a unique solid-phase washing procedure and a chemiluminescent detection system (16, 17) . These provide for immunoassays characterized by high sensitivity and/or broad dynamic working ranges. During the wash cycles, magnets are used to pull the paramagnetic particles to the side of the reaction vessel to allow complete aspiration of the wash fluid. The particles are resuspended by forcefully adding buffer and then gently agitating the vessel. The ACCESS system assays use Lumi-Phos 530 (Lumigen, Inc., Detroit, MI, USA), a dioxetanebased chemiluminescent substrate, which is dephosphorylated upon the addition of alkaline phosphatase, resulting in the release of light. The light emitted is measured by the luminometer and the system converts the signals (relative luminescence units: RLUs) into a sample test result.
Commercial enzyme immunoassay for carcinoembryonic antigen
A commercially available EIA kit, Abbott IMx® CEA (Dainabot Co., Tokyo, Japan), was used for comparative studies. The assay employed as sandwich-type method with two different monoclonal antibodies and was performed according to the instructions of the manufacturer.
Serum samples
Sera from patients with various malignant or benign diseases and from healthy individuals were collected and stored at -20 °C until use. 
Results
Assay protocol obtained
Ten microlitres of calibrators or sera and 40 μΐ of the diluent are incubated for 5 minutes at 37 °C with 50 μΐ of monoclonal antibody F82-61-immobilized particles and with 50 μΐ of monoclonal antibody Fl 1-39 Fab' conjugated with alkaline phosphatase. To eliminate interference from human anti-mouse immunoglobulin antibody, the diluent contains 250 mg/1 of Heterophilic Blocking Reagent (Scantibodies Laboratories, Santee, CA, USA), which is a mixture of purified mouse IgG subclasses. After washing the unbound components, 200 μΐ of the Lumi-Phos® 530 solution are added and the particles are incubated for 5 minutes at 37 °C. Time needed to obtain the first result is less than 15 minutes and thereafter one result is obtained every thirty-six seconds. Results are interpolated automatically from a previously run stored standard curve (stable for up to four weeks). Dose-response curve, detection limit, and hook effect
The CEA calibrators with the concentrations ranging from 0 to 100000 μ^Ι were tested. Figure I represents a typical dose-response curve in which the luminescence obtained is plotted against the CEA calibrator concentra- 
Carryover
The carryover was checked by running a serum sample spiked with a high amount of CEA (10000 μg/l). After analyzing 4 replicates of the zero calibrator, 4 replicates of the sample were then analyzed, as well as 4 replicates of the zero calibrator. The first replicate of the zero calibrator, immediately after the sample, could then be read. Three values obtained by 3 runs were all < 0.1 μg/l, indicating that the carryover was less than 0.001%.
Recovery
The recovery of the assay was also determined by spiking known quantities of CEA to 4 different serum samples, assaying the serum samples and determining the recovery of the amount added. As shown in table 2, analytical recovery ranged from 98 to 104%.
tion. The detection limit of the assay, defined as the concentration of CEA equivalent to the mean luminescence plus 2 standard deviations of the zero calibrator, was calculated based on the respective 10 measurements on three different instruments and found to be 0.04 μg/l. Although the dose-response curve extended up to about 10000 μg/l, moderate high-dose hook effect was observed with the concentrations of 50000 and 100000 μg/l ( fig. 1) . Therefore, the concentrations of calibrators ranging from 0 to 1000 μg/l were selected for determination of CEA in serum samples because in this working range it is virtually impossible to underestimate the concentration due to the hook effect except when the concentration is extremely high (> 100000 μg/l).
Dilution
Three different serum samples containing elevated concentrations of CEA within the assay range were diluted in the calibrator diluent. The samples and their dilutions were then assayed to determine linearity on dilution.
Good linearity was observed in each case ( fig. 2 ).
Interference
Assay interference was assessed by measuring the apparent response of the ACCESS CEA assay to various concentrations of potential interfering substances spiked into human sera. The basal sera and the spiked serum samples were then assayed. As shown in table 3, no interference was demonstrated in any sample with levels Precision study
The intra-assay precision was determined by replication (n = 20) of three serum samples with different CEA levels. To assess inter-assay precision, three concentrations of control sera were assayed in duplicate in at least 20 runs over a period of four weeks. As shown in table 1, the intra-assay CV ranged from 3.0 to 4.7%, while inter-assay CV ranged from 3.4 to 5.6%.
Tab. 1 Intra-and inter-assay precision using control sera.
Intra-assay precision up to 300 mg/1 for bilirubin, 12000 mg/1 for haemoglobin, 50 000 mg/1 for human serum albumin, 8 500 mg/1 for triacylglyerol, or 500000 IU/1 for rheumatoid factor.
Reactivity with carcinoembryonic antigens and related normal antigens
As shown in figure 3 , the ACCESS CEA assay gave no reaction with non-specific cross-reacting antigen (NCA), NCA-2, normal faecal antigen (NFA)-L and NFA-2. Furthermore, the ACCESS CEA assay showed quite homogeneous reactivity with all CEA preparations tested ( fig. 3 ).
Normal cutoff level
The normal cutoff level was determined by analyzing sera from 477 healthy blood donors including smokers aged from 18 to 82 years, showing the values ranging from 0.2 to 9.9 μg/l and the average value of 2.03 μg/l. Since 5 μg/l defined the 95th perceptile in the ACCESS CEA assay and the kit documentation of the IMx CEA assay demonstrates a similar distribution of CEA values in reference populations, we therefore used a tentative common reference limit of 5 μg/l for both the ACCESS CEA and the IMx CEA assays.
Clinical evaluation of the ACCESS CEA assay and comparison with a commercial kit Serum samples of 133 patients with malignant disease and 72 patients with benign disease as well as of 157 normal subjects were tested with the ACCESS CEA and IMx CEA assays. The regression analyses of the AC-CESS CEA assay with the IMx CEA assay showed satisfactory correlations, although the correlation coefficient (r) in sera from normal subjects is slightly lower than those in sera from benign or malignant disease ( fig. 4) . However, when frequency of elevated CEA levels for respective diseases was compared, some differences were seen between the ACCESS CEA assay and the IMx CEA assay (tab. 4). It is evident that the total positive rate for malignant disease showed an definite increase with the ACCESS CEA assay (56.4%) compared to that of the IMx CEA assay (48.9%). In gastric cancer, colorectal cancer, lung cancer, and hepatoma, prominently increased positive rates were observed with the ACCESS CEA assay. The total false positive rate (11.1%) for benign disease with the ACCESS CEA assay was certainly lower than that with the IMx CEA assay (19.4%). Relatively high false positivities with the IMx CEA assay were observed in sera from patients with gastric disease, liver disease or diabetes mellitus.
Tab. In sera from normal individuals, the ACCESS CEA assay gave a decreased false positive rate (4.5%) as compared with the IMx CEA assay (7.6%).
Discussion
Group F anti-CEA monoclonal antibodies have been found to recognize the protein epitopes present on domain B3 of the CEA molecule and to discriminate CEA in tumour tissues from the CEA-related normal antigens (13) . By using a group F monoclonal antibody as tracer antibody, Kuroki et al. have developed a new radioimmunoassay and an EIA with increased tumour specificity and independence from the carbohydrate structure of the CEA molecule (10, 15) . Although those assay systems revealed improved features in cancer sensitivity and efficiency in clinical trials (14, 15) , it has been impossible to employ those assays on the fully automated immunoassay analyzers. In the present study, by using two defined monoclonal antibodies with higher specificity and affinity for CEA, we tried to establish a new immunoassay for CEA, designated ACCESS CEA, which is adapted to the fully automated ACCESS® immunoassay analyzer.
The ACCESS CEA assay employed a one step sandwich-type method using a combination in which monoclonal antibody F82-61 from group C was used as the capture and monoclonal antibody F11-39 from group F as the tracer antibody. Each monoclonal antibody recognizes an epitope present on the N-terminal domain (N) or C-terminal domain (B3) of the CEA molecule, respectively (11, 12) , suggesting that the ACCESS CEA assay detects only the whole CEA molecules with both terminal domains.
The assay range of the ACCESS CEA assay was 0.04-1000 μg/l of CEA and the possible high-dose hook effect was prevented up to 100000 ^ig/l in the working range of the assay. The evaluation of assay performance, such as reproducibility, recovery and dilution tests, and ·»· - interference studies demonstrated the excellent performance of the ACCESS CEA assay. Since many CEA-related antigens have been found in various tissues unrelated to malignant diseases (1), the discrimination of CEA from the normal related antigens, especially from normal faecal antigen-2 in normal adult faeces, seems to be essential for a CEAassay system (5). Although non-specific cross-reacting antigen-2 is a foetal type of CEA (20, 26) and has not yet been found in any normal tissues or tumour tissues, the reactivity with this antigen was also tested in this study. No reactivity of the ACCESS CEA assay with NCA, NFA-1, NFA-2, and NCA-2 indicates that this assay system is able to distinguish CEA from the related normal antigens. The independence of a CEA-assay system from the influence of variations in the sugar chains of the CEA molecule also seems to be very important, because apparent variation in CEA determination appeared to be mainly due to variation in the structures of carbohydrate chains (8) . Furthermore, the expression of epitopes on the sugar chains of the CEA molecule is changeable during synthesis and secretion of CEA by tumour cells, and thus is unstable during the course of malignancy (27) . This may result in false apparent fluctuations of the CEA level in the course of diseases unless the assay system is independent of carbohydrate epitopes. The ACCESS CEA assay showed quite homogeneous reactivity with different CEA preparations tested, showing its independence from the effect of variations in the sugar chains of the CEA molecule.
Since the ACCESS CEA assay certainly showed improved features with respect to the reactivities with purified CEA and related antigen preparations and exhibited excellent assay performance, the clinical features of the ACCESS CEA assay, compared with those of the IMx CEA assay, were estimated in this study. For a fair comparison, the same 362 serum samples from patients with malignant or non-malignant disease, as well as from healthy individuals, were simultaneously assayed by the ACCESS CEA and the IMx CEA assays. The improved diagnostic sensitivity of the ACCESS CEA assay is demonstrated in table 4. In comparison with the IMx CEA assay, 7.5% increases in the diagnostic sensitivity were observed with the ACCESS CEA assay. This was not simply due to an unsuitable cutoff level in the ACCESS CEA assay since the false positive rate with this assay in benign disease or normal subjects was less than that of the IMx CEA assay; that is, the diagnostic specificity (93.4%, 214/229 cases) with the ACCESS CEA assay was also better than that (88.6%, 203/229 cases) with the IMx CEA assay. The ACCESS CEA assay, however, deserves further evaluation using longitudinal collected serum samples from cancer patients to determine how well CEA levels correlate with clinical course.
